All News
ACR20 - Day 3 Report
Here are my highlights from day three, Sunday, of the ACR 2020 Convergence.
Read Article
Abatacept in RA and ILD Patients: Dr Richard Conway (@RichardPAConway) #ACR20
https://t.co/e31VsnXFq5 https://t.co/sCrqLtXFFc
Links:
Dr. John Cush RheumNow ( View Tweet)
#FDA updates #ACR20 @rheumnow
labeling/warning changes:
belimumab- mortality removed
abatacept - angioedema added
baricitinib -hypersensitivity rxn added
gabapentin & pregabalin - respiratory depression added
k dao KDAO2011 ( View Tweet)
Dr Sanchez-Bilbao reports a study of 30 patients with LV GCA. Despite clinical remission with tocilizumab ongoing vascular inflammatory activity identified by PET in 70%. Significant implications for risk of tocilizumab withdrawal. @rheumnow #ACR20 Abstr#1921 https://t.co/f1isidSypn
Richard Conway RichardPAConway ( View Tweet)
Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons. No significant differences in rates between tofa, ADA, MTX, and placebo. @rheumnow #ACR20 Abstr#L04 https://t.co/8RrG0I2Zwm
Richard Conway RichardPAConway ( View Tweet)
Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn
Richard Conway RichardPAConway ( View Tweet)
Tocilizumab in GCA: what happens in the vessels?
Supporting excellent work @KQuinnRheum @petercgrayson earlier at #ACR20, LV-GCA data from Blanco/Gonzalez-Gay et al. Aorta still hot at 10.8±3.7 mo.
in LV-GCA on TCZ, clinical remission ≠ PET remission
#ACR20 ABST1921 @RheumNow https://t.co/ngBVL4rop8
David Liew drdavidliew ( View Tweet)
SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA
Eric Dein ejdein1 ( View Tweet)
@rheumNow #ACR20 #ABSL02 registry data: Pts on biologics more likely to Shield at Home during COVID 19 as opposed to non-biologic or no systemic Rx at all. Such stringent mitigation tactics may contribute to the reported lower risk of adverse COVID-19 outcomes in biologics Pts
Olga Petryna DrPetryna ( View Tweet)
Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP):
- 65% of pts w/ SpA had bone marrow edema (BME) mainly in the iliac quad of intermed middle segment
- 20% w/o SpA had BME mainly in antero-middle quad. #Abst1535 #ACR2020 @RheumNow https://t.co/1ptGGUbUS4
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
How often do you perform NFC in suspected SSc patients? @RheumNow #ACR20
sheila RHEUMarampa ( View Tweet)
Frequency and Anatomic Distribution of MRI Lesions in the Sacroiliac Joints of Healthy Subjects and Patients with Spondyloarthritis. Dr Hecquet. #ACR20 @RheumNow BME was seen in 65% patients with Spa and in 20% without spondyloarthritis predominantly in the antero-middle quadrant https://t.co/OUYz2FQ5Yp
Sole RetamozoSole ( View Tweet)
Accdg to this study, no association was found between IFN levels and cognitive function in SLE pts (even after considering factors like SLE dse duration)
Interesting! @RheumNow #ACR20 abs1788 @ZahiTouma https://t.co/F4j8H1CWJ9
sheila RHEUMarampa ( View Tweet)
Abst#L01. Pt is on MTX/ADA for RA and asks you about their COVID risk. What do you counsel your patient? #ACR20 @RheumNow.
Eric Dein ejdein1 ( View Tweet)
#osteoarthritis Rx with #tanezumab - analgesic or DMOAD? RCT in knee OA of 3021 pts & only 1312 completed Rx. Tanezumab > improvement in pain v NSAIDs but NO diff in MCII and pt acceptable symptoms (PASS) over time #ACR20 #ACRbest abstr#1641 @RheumNow @CRASCRRheum https://t.co/x75ncz16uP
Janet Pope Janetbirdope ( View Tweet)
Poll results are in! Most would like to wait for a phase III before prescribing MMF with pegloticase in refractory gout. @RheumNow #ACR20 https://t.co/45MpFliDkE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials https://t.co/70oOHXihFb #SLE #zoster x 4-5 times increase in zoster
Peter Nash drpnash ( View Tweet)
How do we dose maintenance rituximab in AAV to optimise B cell depletion but minimise hypogammaglob?
Drug levels may be the answer. In this cohort (n=61)
trough >550ng/mL: all B cell depleted
>1000ng/mL: all got hypogammaglob
very interesting concept!
#ACR20 ABST1438 @RheumNow https://t.co/0pcl0BW2Tv
David Liew drdavidliew ( View Tweet)
Data from BIOBADASER 3 showed that there was a ⬇ in the incidence of S. pneumonia-related infxns in RA pts on b/tsDMARD after receiving the stepwise combined vax scheme (conj+PS) @RheumNow #ACR20 abs1465 #VaccinesWork https://t.co/KlestmKfaO
sheila RHEUMarampa ( View Tweet)
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
Dr. John Cush RheumNow ( View Tweet)
